Shares of Smith & Nephew Plc ( SNN ) are trading higher on Friday. Smith+Nephew offers a medical technology portfolio across orthopedics, sports medicine, ENT, and advanced wound management.

In an SEC filing, Smith & Nephew ( SNN ) reported that an activist investor, Cevian Capital, had taken a 5% stake.

Citing a partner at the Swedish fund, Bloomberg noted that Smith & Nephew ( SNN ) has not generated shareholder value for many years. “Cevian sees the potential to create significant long-term value by improving the operating performance of the company’s businesses.”

Medical technology firm’s share price performance in the past five years has been lacklustre.

Its market capitalization has fallen from 17 billion pounds in 2019 to 8.6 billion pounds (around $11 billion), with supply chain issues and changes at the top hitting the company’s performance.

Financial Times notes that Smith & Nephew ( SNN ) is the second-largest company in the sports management and advanced wound management sectors, while it is the fourth-largest maker of hip and knee implants.

“Cevian sees the potential to create significant long-term value by improving the operating performance of the company’s businesses,” Friederike Helfer, a partner in the fund, told the Financial Times.

In a statement, Smith & Nephew ( SNN ) said it had “an open dialogue with our shareholders and will continue to engage with Cevian, as we do with all of our shareholders.”

In the first quarter 2024 trading update, the company said, "Revenue growth in the first quarter was driven by solid performance in our Orthopaedics and Sports Medicine & ENT businesses, partially offset by some anticipated softness in Advanced Wound management.”

Underlying revenue growth is expected between 5.0%-6.0% (4.3% to 5.3% reported), and the trading profit margin is expected to be at least 18.0%.

Price Action: SNN shares are up 8.04% at $27.15 at last check Friday.

Image from Shutterstock

Read Next:

British MedTech Firm Smith & Nephew Seeks To Adopt US-Inspired Pay Policy to Navigate Shareholder Skepticism.